Joe Biden shares smiling selfie with Jill and their cat in first post since cancer diagnosis
Joe Biden has been diagnosed with an aggressive prostate cancer that has spread to his bones.
In a statement released Sunday afternoon, Joe Biden’s office confirmed he has been diagnosed with an aggressive form of prostate cancer that has metastasized to the bone. The announcement follows weeks of mounting speculation over his health and comes as a sobering moment for supporters and political observers alike. Since the diagnosis, Biden broke his silence with a public post, his first since the news emerged, where he acknowledged the gravity of his condition.
Biden breaks silence with a selfie post-cancer diagnosis announcement
In his first post on X since his cancer diagnosis announcement, the former president wrote, “Cancer touches us all. Like so many of you, Jill and I have learned that we are strongest in the broken places. Thank you for lifting us up with love and support.”
Supporters reacted to Biden's post as one user wrote, “Keep fighting Joe. You’re a fighter. We all love you.” Another user wrote, “We love you Joe. You will get through this!” A third user wrote, “Praying that you are restored to perfect health.”
What is the impact of age on prostate cancer progression?
According to a large population-based study reported by Daskivich et al. (2014), older age is a significant risk factor for developing prostate cancer, with men aged 75 years and older being significantly more likely to be diagnosed with high-risk or more aggressive forms of the disease compared to younger men. The study found that older men had a higher proportion of advanced-stage and high-grade tumors at diagnosis, indicating that both the incidence and severity of prostate cancer increase with age.
Also Read: How dangerous is prostate cancer? Here's what to know after Joe Biden's diagnosis
Treatment options for advanced prostate cancer
Treatment for aggressive prostate cancer has become increasingly personalized, often guided by genomic biomarkers and the unique characteristics of the disease. While combination therapies, such as androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI), with or without chemotherapy, are now considered standard care for many patients, their adoption in real-world settings remains uneven.
Some of the treatment options include:
Hormone Therapy (Androgen Deprivation Therapy, ADT)
Androgen Receptor Pathway Inhibitors (ARPI)
Chemotherapy
PARP Inhibitors
Radioligand Therapy
Immunotherapy
Effective management must also take into account a patient’s overall health, existing comorbidities, and personal preferences, alongside the potential side effects of each treatment option.
